Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

chronic graft versus host disease - Clinical Profile, Treatments & Trials | Kisho | Kisho

Rare Disease

chronic graft versus host disease

MONDO:0020547

Also known as:GVHD, chronicgraft versus host disease, chronicchronic GVHD

Find Clinical TrialsTrials

Overview

Chronic graft versus host disease (GVHD) is a complication that can occur after a stem cell or bone marrow transplant in which the newly transplanted donor cells attack the transplant recipient's body. Symptoms may include skin rash, mouth sores, dry eyes, liver inflammation, development of scar tissue in the skin and joints, and damage to the lungs. The exact cause of chronic GVHD is unknown.It likely results from a complex immune-mediated interaction between the donor and recipient cells.Chronic GVHD is treated with prednisone or other similar anti-inflammatory or immunosuppressive medications.

Treatments2 FDA approved, newest 2024

Clinical Trials25 registered · 13 recruiting

Patient Orgs1 organizations · National Bone Marrow Transplant Link

Clinical Presentation

Built from Human Phenotype Ontology (HPO) phenotype annotations and GeneReviews clinical descriptions. Features represent findings documented across known cases — not an exhaustive list of possible symptoms.

Features include very common findings: Poor wound healing, Thickened skin, and Intermittent generalized erythematous papular rash; and common findings: Xerostomia, Recurrent corneal erosions, Photophobia, and Skin color changes (abnormality of skin pigmentation) and others. 53 total HPO annotations.

Organ System	Phenotype Count	Example Features
Digestive system	12	Elevated circulating hepatic transaminase concentration, Ascites, Diarrhea

Diagnosis

Biomarker and diagnostic research for chronic graft versus host disease has been reported in the published literature.

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

2 FDA-approved treatments are available for chronic graft versus host disease, including AXATILIMAB-CSFR (NIKTIMVO, approved 2024) and IBRUTINIB (IMBRUVICA, approved 2022). An additional 1 compound holds orphan drug designation.

Approved Therapies

Brand Name	Generic Name	Mechanism	Approved	Market Status

Prognosis

Phenotype severity distribution: 3 very common features, 13 common features.

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

25 clinical trials registered, 13 recruiting. Interventions under study include other interventions, drug therapy, medical devices, and procedural interventions. Pipeline includes 2 PHASE3, 8 PHASE2, 9 PHASE1. Research is sponsored by a mix of industry and academic institutions.

NCT ID	Title	Phase	Sponsor	Status
[NCT05675930](https://clinicaltrials.gov/study/NCT05675930)

Data assembled from 6 of 12 sources · Last updated Sep 19, 2026, 6:05 PM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Patient Support

Patient Advocacy Groups

View all PAGs →

National Bone Marrow Transplant LinkPrimary Focus

USWebsite ↗

Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.

Are you a patient organization not listed here? Claim this page to be listed and embed this content on your site — free.

Medical References

External Resources

Orphanet

European rare disease database

Orphanet:99921

GARD

Genetic and Rare Diseases Info Center

GARD:10964

Questions for Your Care Team

→What are the benefits and potential side effects of NIKTIMVO for managing chronic graft versus host disease?
→Are any of the 25 active clinical trials a good fit for my situation?
→Are there specialists or centers of excellence for this condition in my area?
→How can I connect with National Bone Marrow Transplant Link and other patient organizations for support?

← Back to All Diseases

Brand Name	Generic Name	Sponsor	Designated	Exclusivity End	Designation Status
autologous lymphocytes depleted ex vivo of immunoreactive T cells using 4,5	autologous lymphocytes depleted ex vivo of immunoreactive T cells using 4,5	Kiadis Pharma Netherlands B.V.	2008	—	Withdrawn

Research Type	Count	% of Total
Research summaries	44	40%
Disease patterns and progression	21	19%
Clinical study results	17	15%
Laboratory research	14	13%
Patient case studies	8	7%
Other research	3	3%
New treatment approaches	3	3%
Testing and diagnosis research	1	1%

Kisho

chronic graft versus host disease

Overview

Clinical Presentation

Diagnosis

Treatment

Approved Therapies

Prognosis

Research Landscape

Patient Support

Patient Advocacy Groups

Medical References

External Resources

Orphanet

GARD

Questions for Your Care Team

Questions for Your Care Team

Explore clinical features

Orphan Drug Designations

Clinical Trials

Recent Publications

Latest News & Developments

Graviton BioScience Corporation Announces Publication of Positive Ph1b Trial Results for GV101 (TDI01) in Chronic Graft versus Host Disease in Signal Transduction and Targeted Therapy, by Beijing Tide Pharmaceutical

Toward Standardized Screening for Chronic GVHD: Insights from the Engraft Learning Network.

Successful use of ruxolitinib in steroid-refractory chronic GvHD affecting central nervous system: a case report.

Proposal for Diagnostic Criteria for Manifestations of Chronic Graft-versus-Host Disease in Peripheral Nervous System and Muscles.

Ibrutinib Receives Orphan Drug and Breakthrough Therapy Designation for cGVHD | BioPharm International

chronic graft versus host disease

Overview

Clinical Presentation

Diagnosis

Treatment

Approved Therapies

Prognosis

Research Landscape

Patient Support

Patient Advocacy Groups

Medical References

External Resources

Orphanet

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Explore clinical features

Orphan Drug Designations

Clinical Trials

Recent Publications

Latest News & Developments

Graviton BioScience Corporation Announces Publication of Positive Ph1b Trial Results for GV101 (TDI01) in Chronic Graft versus Host Disease in Signal Transduction and Targeted Therapy, by Beijing Tide Pharmaceutical

Toward Standardized Screening for Chronic GVHD: Insights from the Engraft Learning Network.

Successful use of ruxolitinib in steroid-refractory chronic GvHD affecting central nervous system: a case report.

Proposal for Diagnostic Criteria for Manifestations of Chronic Graft-versus-Host Disease in Peripheral Nervous System and Muscles.

Ibrutinib Receives Orphan Drug and Breakthrough Therapy Designation for cGVHD | BioPharm International